...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Upcoming CVOT results

Bear was this achieved with very high absolute risk patients or lower risk patients?

"Amarin's REDUCE-IT achieved a very significant 26% RRR for 3-point MACE composite secondary outcome and very significant 25% RRR for 5-point MACE primary outcome. Additionally, REDUCE-IT achieved a significant 20% RRR (p=0.03) in cardiovascular death."

 

Koo

 

 

Share
New Message
Please login to post a reply